ClinicalTrials.gg
CompletedNCT00631943Updated Jan 22, 2021

A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain

A Phase 3 interventional study of Pregabalin (Lyrica) in Neuralgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 6 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-22.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
112
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.

Enrollment
23rd of 50
112 · median 109
Started
2004
the only one that year
Phase 3
18 of 50
1 open now
Registered
11th of 50
by date
Lead sponsor
12 of 50
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 50 studies testing pregabalin in Neuralgia, this one is the 23rd largest by enrollment, is the only one that started in 2004, is one of 18 in phase 3, and was the 11th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Neuralgia studies recruiting now, 78 (51%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing pregabalin in Neuralgia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Lyrica in Indian patients with nerve pain

03

Conditions studied

  • Neuralgia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Peripheral neuropathic pain
  • Score of at least 40 mm on the VAS of the SF-MPQ at screening and baseline
  • Completion of at least 4 daily pain diary entries with an average daily pain score of at least 4 over the 7 days prior to baseline

Exclusion criteria

Exclusion criteria:

(none)

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    1

    Drug: Pregabalin (Lyrica)

Interventions

  • Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Short Form McGill Pain Questionnaire (SF-MPQ) visual analog score (VAS)

    Time frame: Weeks 1 and 2 and end of treatment

  2. Change from baseline in weekly mean pain scores

    Time frame: Weeks 1 and 2 and end of treatment

Secondary outcomes

  1. Change from baseline in Euro Quality of Life Questionnaire (EQ-5D) scores

    Time frame: End of treatment

  2. Adverse events and laboratory value changes

    Time frame: Weeks 1 and 2 and end of treatment

  3. Change from baseline in weekly mean sleep interference score

    Time frame: Weeks 1 and 2 and end of treatment

  4. Change from baseline in sensory, affective, and total components of the pain descriptor score and the Present Pain Intensity (PPI) of the SF-MPQ

    Time frame: Weeks 1 and 2 and end of treatment

  5. Change from baseline in Patient Global Impression of Change (PGIC)

    Time frame: Weeks 1 and 2 and end of treatment

  6. Change from baseline in Clinical Global Impression of Change (CGIC)

    Time frame: Weeks 1 and 2 and end of treatment

  7. Change from baseline in pain interference scores on the Brief Pain Inventory (BPI ) Short-Form

    Time frame: End of treatment

07

Study locations

6 sites
  • Pfizer Investigational Site
    Bangalore, Karnataka / India 560 034, India
  • Pfizer Investigational Site
    Bangalore, Karnataka 560054, India
  • Pfizer Investigational Site
    Mumbai, Maharashtra 400 012, India
  • Pfizer Investigational Site
    Maharashtra, Mumbai 400 007, India
  • Pfizer Investigational Site
    Chennai, Tamil Nadu 600 004, India
  • Pfizer Investigational Site
    Chennai, Tamil, Nadu 600 013, India
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2008
First posted
Mar 10, 2008
Start
Nov 2004
CompletionActual
Mar 2005
Last update
Jan 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00631943
Responsible party
Sponsor
First posted
Mar 10, 2008
Start date
Nov 2004
Completion
Mar 2005
Last update
Jan 22, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion